Can Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Attain EPS Target Of $1.06?

Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Valeant Pharmaceuticals International, Inc.

Siliq is unlikely to be the solution to all of Valeant's problems, but it could be a growing source of much-needed revenue for the company over the next few years. Stifel Nicolaus reaffirmed a "buy" rating and issued a $45.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, February 9th. Kistler Tiffany Companies LLC boosted its position in shares of Valeant Pharmaceuticals International by 95.5% in the third quarter.

Valeant Pharmaceuticals International, Inc. had its "market perform" rating reiterated by analysts at BMO Capital Markets. Currently, the stock has a 1 Year Price Target of $22.39. Company's distance from 20 day simple moving average is 10.70% and distance from 50-Day simple moving average is 12.53%. The low EPS estimate is $1.07, while the high EPS estimate is $1.36.

"We reiterate our August 2016 expectation to pay down $5 billion of debt from divestiture proceeds and free cash flow within an 18 month timeframe of that initial statement", Umer Raffat of Evercore ISI wrote in a note.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) early Tuesday posted better than expected fourth quarter earnings results and offered an in-line outlook for 2017, as it redoubles its efforts to stem the tide of negative sales growth. Finally, Sheaff Brock Investment Advisors LLC raised its stake in shares of Valeant Pharmaceuticals International by 281.2% in the second quarter. The High Revenue estimate is predicted as 2.5 Billion, while the Low Revenue Estimate prediction stands at 2.28 Billion.

As a result, he believes the company's revenue and EBITDA guidance "could be adjusted even lower over the course of the year" as these acquisitions close.

Full year 2016 revenue in the Bausch & Lomb/International segment were $4.61 billion, up from sales of $4.60 billion for 2015. "(VRX)" was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was stolen and republished in violation of USA and worldwide copyright & trademark laws.

VRX stock fell anyway; an initial plunge below $15 per share being grabbed by bargain hunters, with a price in the afternoon of $15.03. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 3.32. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Thomas W. Sr. Brokerages covering Valeant Pharmaceuticals International, Inc. are projecting the stock to smash $25.583 over the coming 52-weeks. The shares were acquired at an average price of $14.73 per share, with a total value of $73,650.00. Valeant sunk nearly 10% to $1.53 per share in Tuesday morning trading. The disclosure for this sale can be found here.

Several large investors have recently bought and sold shares of VRX.

Valeant also said it plans to relaunch its sexual dysfunction drug Addyi in the U.S. Addyi, acquired by the company in its 2015 buyout of Sprout Pharmaceuticals, is meant to treat low sexual desire in women.



Other news